These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16878361)

  • 1. [Meta-analysis finds cardioprotective effects: renaissance of hormone replacement therapy? Interview by Katharina Arnheim].
    Kuhl H
    MMW Fortschr Med; 2006 Jun; 148(26):14. PubMed ID: 16878361
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hormone replacement therapy and cardiovascular prevention: many statements, some doubts].
    Motolese M
    Ital Heart J Suppl; 2003 Jul; 4(7):545-58. PubMed ID: 14558283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Post-menopausal hormone replacement therapy after 70 years of age. Is it to be administered?].
    Bouillanne O; Piette F
    Rev Prat; 1998 Sep; 48(13):1398-400. PubMed ID: 10050616
    [No Abstract]   [Full Text] [Related]  

  • 4. Controversial aspects of hormone replacement therapy upon cardiovascular mortality and morbidity of women in menopause.
    Rosano GM; Mercuro G
    G Ital Cardiol; 1999 Sep; 29(9):999-1003. PubMed ID: 10514956
    [No Abstract]   [Full Text] [Related]  

  • 5. Hormone therapy and cardiovascular disease in the early postmenopause: the WHI data revisited.
    Pines A; Sturdee DW; Birkhäuser MH;
    Climacteric; 2007 Jun; 10(3):195-6. PubMed ID: 17487646
    [No Abstract]   [Full Text] [Related]  

  • 6. [For prevention of cardiovascular diseases: statins in old age?].
    MMW Fortschr Med; 2006 Sep; 148(38):16. PubMed ID: 17036955
    [No Abstract]   [Full Text] [Related]  

  • 7. Questioning the cardioprotective action of hormone replacement therapy in postmenopausal women.
    Mascitelli L; Goldstein MR; Pezzetta F
    J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):657-8. PubMed ID: 19424079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Postmenopausal hormone replacement therapy and cardiovascular disease].
    Høibraaten E
    Tidsskr Nor Laegeforen; 2002 Jun; 122(16):1564-5. PubMed ID: 12119783
    [No Abstract]   [Full Text] [Related]  

  • 10. Postmenopausal hormone replacement therapy and prevention: no chance for celebration? What should doctors do? A personal opinion.
    Rossi R; Modena MG
    Ital Heart J; 2002 Dec; 3(12):693-8. PubMed ID: 12611118
    [No Abstract]   [Full Text] [Related]  

  • 11. Statement on results of the HERS II trial on hormone replacement therapy.
    American College of Obstetricians and Gynecologists
    Ginecol Obstet Mex; 2002 Aug; 70():406-8. PubMed ID: 12448046
    [No Abstract]   [Full Text] [Related]  

  • 12. Breast cancer risk: is postmenopausal hormone therapy ever safe?
    Ganz PA
    Menopause; 2005; 12(6):653-5. PubMed ID: 16278604
    [No Abstract]   [Full Text] [Related]  

  • 13. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.
    Rosano GM; Maffei S; Andreassi MG; Vitale C; Vassalle C; Gambacciani M; Stramba-Badiale M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):85-92. PubMed ID: 19145119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How we got to the Women's Health Initiative hormone replacement trial.
    Gambone JC
    J Am Osteopath Assoc; 2003 Feb; 103(2 Suppl 2):S1-2. PubMed ID: 12625630
    [No Abstract]   [Full Text] [Related]  

  • 15. Health risks after cessation of postmenopausal hormone therapy.
    Pines A; Sturdee D; Birkhäuser M;
    Climacteric; 2008 Jun; 11(3):179-80. PubMed ID: 18568782
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The story of the reversal of opinion about hormone replacement therapy and cardiovascular disease].
    Løkkegaard EC
    Ugeskr Laeger; 2005 Mar; 167(10):1166-70. PubMed ID: 15810574
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials.
    Lobo RA
    Arch Intern Med; 2004 Mar; 164(5):482-4. PubMed ID: 15006823
    [No Abstract]   [Full Text] [Related]  

  • 19. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Bittner V
    Expert Opin Pharmacother; 2009 Sep; 10(13):2041-53. PubMed ID: 19563274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmenopausal hormone therapy in clinical perspective.
    Hodis HN; Mack WJ
    Menopause; 2007; 14(5):944-57. PubMed ID: 17353803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.